Partners' Directory

  Home   Search   Join the Partnership   Login

Contact General Specializations in Countries Contribution to the Global Plan Declaration

View this partner's profile

Organization Contact Information

Name: Ecole Polytechnique Fédérale de Lausanne (EPFL)
Street 1: SV-GHI-UPCOL
Street 2: Station 19
City: Lausanne
Province: Vaud
Post Code: CH-1015
Country: Switzerland
Phone: +41 21 693 17 87
Organization Email:
Web Site:
Other Online Presence:

Focal Point Contact Information

Salutation: Prof
First Name: Stewart
Last Name: COLE
Title: Professor & Director
Phone: +41 21 693 18 51

Alternate Focal Point Contact Information

Salutation: Ms
First Name: Suzanne
Last Name: Lamy
Phone: +41 21 693 17 87

General Information

Board Constituency: Technical agencies
Is your organization legally registered in your country: Yes
If yes, please enter your registration number:
Organization Type - Primary: Academic / Research Institution
Organization Type - Secondary: None
Organization Description:
The Global Health Institute (GHI) is contributing to the understanding, diagnosis, prevention and treatment of infectious diseases, which still claim 18 million human lives each year and account for half of the deaths in the developing world. The GHI comprises 9 groups, all engaged in different facets of research linked to human health but with strong emphasis on diseases of truly global importance such as HIV/AIDS, tuberculosis and malaria. Basic mechanisms of host-pathogen interactions and innate and acquired immunity against pathogens are being studied using multidisciplinary approaches. A unique feature of the GHI is its ability to tackle crucial world health issues by harnessing cutting edge technologies developed at EPFL and elsewhere. Among these the nanotechnologies, microengineering and informatics are proving particularly powerful at underpinning drug discovery and vaccinology research. Intensification of current research themes by applying novel technological innovations will continue and elucidating the basis of genetic predisposition to infectious diseases is also a priority as this will open new avenues for diagnostics and personal medicine.
Do you know about the UNHLM declaration:

Specializations / Areas of Work

Research and Development

Other Organization Information

Total number of staff in your organization: 11 - 25
Number of full-time staff who are directly involved with TB: 11 - 25
Number of part-time staff who are directly involved with TB: 0
Number of volunteers who are directly involved with TB: 0
How did you hear about the Stop TB Partnership: Attendance at a TB related event
If you were informed or referred by another partner of the Stop TB Partnership please tell us who:
Why do you wish join the Stop TB Partnership: Network with other partners
Are you a member of a Stop TB national partnership: No
Are you in contact with your national TB programme: Yes
Please tell us how your organization is contributing to your country's national TB control plan:
A multidisciplinary approach is being used by UPCOL to tackle major public health problems such as tuberculosis (TB) and leprosy. The unit comprises experts in genomics, functional genomics, bioinformatics, biochemistry, chemistry and structural biology. Using genome biology as a platform we are actively involved in discovering new drugs to treat TB and believe that knowledge gained through discovery must be broadly and swiftly disseminated. Given the global importance of the TB problem, we are trying to strike the correct balance between competition and collaboration. In addition to numerous collaborations in the context of the EPFL and the framework of NM4TB, we are also collaborating with other leading European and American scientists such as Professor Pedro Alzari, Professor Patrick Brennan, Dr. Roland Brosch and Dr. Christophe Guilhot.

Geographical Reach

Which country is your headquarters located in: Switzerland
Which countries do you do operate in:
(This includes countries you are conducting activities in)


Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below:

Drug-Resistant TB:
Our group leads the MM4TB consortium

New TB Drugs:
Our group leads the MM4TB consortium


Declaration of interests:
Hold patents for TB drug candidates and have worked as a consultant for pharma.

Application date: September 29, 2008
Last updated: October 4, 2012